23andMe

CORRECTION/RETRACTION: New to The Street Announces Four Corporate Interviews on its 525th Show, Airing on the Fox Business Network, Monday, October 30, 2023, at 10:30 PM PT

Retrieved on: 
Friday, October 27, 2023
Ethos, Dark, Rat, American College, Social media, FRA, Pressure, Genetics, Elective surgery, Interview, Third party, Disease, Hacking, Record, Cannabinoid, IP, Pain, Birthday, Sale, Veterinarian, Cat, ACVS, American College of Veterinary Surgeons, Injury, Internet, Osteoarthritis, Dog, Innovation system, Web page, 23andMe, Horse, FMW, BEC, Food, Coffee, Medical cannabis, Conference, Cosmetics, CSE, Quality of life, Animal, Privacy, Epilepsy, Communication, Email spoofing, FDA, Water, Patent, OTCQX, Absorption, PROMO, Electricity, OTCQB, Television, Cryptocurrency, CBD, Street

New to The Street’s 525th TV episode features the following four (4) Companies and their representatives:

Key Points: 
  • New to The Street’s 525th TV episode features the following four (4) Companies and their representatives:
    1).
  • The study demonstrated the efficacy of Spryng as an excellent, non-invasive alternative in treating dogs with cranial cruciate disease and injuries.
  • John believes as more published studies prove the viability of Spryng more veterinarians will adopt it as a front-line treatment.
  • PETV's Spryng is becoming more widely known as an effective disruptive technology for treating dogs, horses, and cats with osteoarthritis.

New to The Street Announces Five Corporate Interviews on its 525th Show, Airing on the Fox Business Network, Monday, October 30, 2023, at 10:30 PM PT

Retrieved on: 
Friday, October 27, 2023
Ethos, Rat, American College, Social media, FRA, Pressure, Genetics, Elective surgery, Bureau, Interview, Third party, Disease, Silver, Hacking, Big Nuz, Record, Cannabinoid, BLM, IP, Mining, Pain, Sale, Veterinarian, Cat, ACVS, American College of Veterinary Surgeons, Injury, Internet, Osteoarthritis, Dog, Innovation system, Horse, 23andMe, FMW, BEC, Food, Coffee, Medical cannabis, Conference, Cosmetics, Bureau of Land Management, CSE, Quality of life, Animal, Privacy, Epilepsy, Communication, Email spoofing, FDA, Water, Patent, OTCQX, LG, Absorption, PROMO, Electricity, OTCQB, State Street Corporation, Television, Cryptocurrency, CBD, Street

Gold/Silver Mining – Lahontan Gold Corp.'s (OTCQB: LGCXF) (TSXV: LG) ($LGCXF) interview with Kimberly Ann, Founder, CEO, President, and Director.

Key Points: 
  • Gold/Silver Mining – Lahontan Gold Corp.'s (OTCQB: LGCXF) (TSXV: LG) ($LGCXF) interview with Kimberly Ann, Founder, CEO, President, and Director.
  • The study demonstrated the efficacy of Spryng as an excellent, non-invasive alternative in treating dogs with cranial cruciate disease and injuries.
  • Spryng is a naturally derived matrix of building proteins that mimics collagen tissue, significantly improving animals with cruciate damage and disease.
  • John believes as more published studies prove the viability of Spryng more veterinarians will adopt it as a front-line treatment.

Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise

Retrieved on: 
Monday, October 23, 2023
Colon, Oncolytics Biotech, Genetics, News, Lung, Disease, Risk, Messenger, Lijun International Pharmaceutical (Holding) Co. Ltd., BNTX, Glycine, BioNTech, G12, Hope, RET, Prostate cancer, BRCA2, Cancer, Immune system, Pancreatic cancer, ORR, Hand, University, Roche, Therapy, Patient, Natural history of disease, DNA, CR, Eli Lilly and Company, CAD, 23andMe, JD, OTC, Eli Lilly, FOLFIRINOX, BRCA, Research, Clinical trial, BBB National Programs, Survival rate, Aspartic acid, Valine, Woman, ONC, MD Anderson Cancer Center, TSX, PCCP, Survival, FDA, Lilly, Attention, AACR, Incidence, BRCA1, New View (Eleanor Friedberger album), MBA, KRAS, Entrepreneurship, Breast, Diagnosis, Prostate, FTD, Pharmaceutical industry, Medical imaging, Vaccine, Nature

VANCOUVER, BC, Oct. 23, 2023 /PRNewswire/ -- USA News Group - Despite being a relatively rare form of cancer, pancreatic cancer remains one of the deadliest in the oncology field, the third leading cause of cancer death in the USA. Still not fully understood, pancreatic cancer's 5-year survival rate is currently only 12%. New analysis of data from the National Program of Cancer Registries database, covering around 65% of the US population, suggests that the incidence of pancreatic cancer among individuals younger than 55 years is increasing more rapidly than in those 55 years or older, and also more quickly in women than in men. As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder. Thankfully, within the biotech sector, there have been plenty of developments giving hope in the fight against pancreatic cancer, including those from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Eli Lilly and Company, Roche Holding AG (OTC:RHHBY), BioNTech SE (NASDAQ:BNTX), and even 23andMe Holding Co (NASDAQ:ME).

Key Points: 
  • As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder .
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • The BRCA1 and BRCA2 variants may also be associated with an increased risk for prostate cancer, pancreatic cancer, and potentially other cancers.
  • "It's an important milestone that shows we're headed in the right direction – and this means so much to all those affected by pancreatic cancer."

Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise

Retrieved on: 
Monday, October 23, 2023
Colon, Oncolytics Biotech, Genetics, News, Lung, Disease, Risk, Messenger, Lijun International Pharmaceutical (Holding) Co. Ltd., BNTX, Glycine, BioNTech, G12, Hope, RET, Prostate cancer, BRCA2, Cancer, Immune system, Pancreatic cancer, ORR, Hand, University, Roche, Therapy, Patient, Natural history of disease, DNA, CR, Eli Lilly and Company, CAD, 23andMe, JD, OTC, Eli Lilly, FOLFIRINOX, BRCA, Research, Clinical trial, BBB National Programs, Survival rate, Aspartic acid, Valine, Woman, ONC, MD Anderson Cancer Center, TSX, PCCP, Survival, FDA, Lilly, Attention, AACR, Incidence, BRCA1, New View (Eleanor Friedberger album), MBA, KRAS, Entrepreneurship, Breast, Diagnosis, Prostate, FTD, Pharmaceutical industry, Medical imaging, Vaccine, Nature

VANCOUVER, BC, Oct. 23, 2023 /PRNewswire/ -- USA News Group - Despite being a relatively rare form of cancer, pancreatic cancer remains one of the deadliest in the oncology field, the third leading cause of cancer death in the USA. Still not fully understood, pancreatic cancer's 5-year survival rate is currently only 12%. New analysis of data from the National Program of Cancer Registries database, covering around 65% of the US population, suggests that the incidence of pancreatic cancer among individuals younger than 55 years is increasing more rapidly than in those 55 years or older, and also more quickly in women than in men. As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder. Thankfully, within the biotech sector, there have been plenty of developments giving hope in the fight against pancreatic cancer, including those from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Eli Lilly and Company, Roche Holding AG (OTC:RHHBY), BioNTech SE (NASDAQ:BNTX), and even 23andMe Holding Co (NASDAQ:ME).

Key Points: 
  • As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder .
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • The BRCA1 and BRCA2 variants may also be associated with an increased risk for prostate cancer, pancreatic cancer, and potentially other cancers.
  • "It's an important milestone that shows we're headed in the right direction – and this means so much to all those affected by pancreatic cancer."

Esther Wojcicki Invests in Leading P2P Tutoring Platform, Joins as Chief Education Advisor to Launch ‘Moonshot Campus Initiative’

Retrieved on: 
Thursday, September 28, 2023
Education, Apps, Applications, Technology, Mobile, Wireless, Other Education, Internet, University, Learning, 23andMe, Partnership, Pediatrics, Classroom, The New York Times, Stanford University, Parent, Economist, Pell, Creativity, Student, Trust, Samyr Lainé, Wójcicki, Physics, Tutoring, Nursing, Tourism, Knack

Knack, the fastest-growing peer-to-peer college tutoring platform, has added Esther Wojcicki as a strategic investor and has appointed her as Chief Education Advisor.

Key Points: 
  • Knack, the fastest-growing peer-to-peer college tutoring platform, has added Esther Wojcicki as a strategic investor and has appointed her as Chief Education Advisor.
  • “Knack is fostering one of the most important parts of learning, especially in the college environment.
  • Peer-to-peer is the most effective way to learn, regardless of the subject matter,” said Wojcicki.
  • Knack is the leading student success platform transforming tutoring in direct partnership with dozens of higher education institutions across the nation.

23andMe Granted New FDA Clearance to Report Additional BRCA Variants

Retrieved on: 
Thursday, August 31, 2023
Lijun International Pharmaceutical (Holding) Co. Ltd., Pancreatic cancer, 23andMe, PCCP, DNA, Disease, Sanger, Ashkenazi Jews, Genetics, BRCA1, Food and Drug Administration, Cancer, Breast, Prostate, PGS, Marketing, Risk, Artificiality, Genetic testing, Entrepreneurship, BRCA2, BRCA, Health, FDA, Ovarian cancer, Gene, African Americans, Food, Saliva, Breast cancer, Prostate cancer, Birth control, Medical device, Pharmaceutical industry, Dietary supplement

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today announced the Company has received a U.S. Food and Drug Administration (FDA) 510(k) clearance to expand its existing BRCA1/BRCA2 (Selected Variants) Genetic Health Risk Report*. The clearance allows 23andMe to report an additional 41 variants in the BRCA1 and BRCA2 genes known to be associated with higher risk for breast, ovarian, prostate and pancreatic cancer. 23andMe received the first FDA authorization for a direct-to-consumer genetic test for cancer risk in 2018 to report 3 variants in the BRCA1 and BRCA2 genes, primarily found in people of Ashkenazi Jewish descent. Many of the 41 BRCA variants added through this clearance are known to have a higher rate of occurrence in populations traditionally underserved by genetic testing, including the African American and Hispanic/Latino communities. This marks the Company’s fourth FDA clearance for genetic cancer risk.

Key Points: 
  • The clearance allows 23andMe to report an additional 41 variants in the BRCA1 and BRCA2 genes known to be associated with higher risk for breast, ovarian, prostate and pancreatic cancer.
  • In addition to the 510(k) clearance, the FDA also granted 23andMe the first-ever Predetermined Change Control Plan (PCCP), which allows the Company to add additional validated BRCA1 and BRCA2 variants and associated cancer risk information to its BRCA1/BRCA2 (Selected Variants) report without additional premarket review.
  • 23andMe also underwent robust analytical validation in order to meet FDA requirements to add variants to the BRCA1/BRCA2 (Selected Variants) report.
  • This clearance is the eighth pre-market authorization granted by the FDA to 23andMe covering its multiplexed Personal Genome Service.

Global Consortium Identifies Novel Parkinson's Genetic Risk Factor in African Populations

Retrieved on: 
Thursday, August 24, 2023
Alcohol-related dementia, PD, Alzheimer's disease, Ashkenazi Jews, The Michael J. Fox Foundation, Doctor of Philosophy, MJFF, MD, Risk, Genetic programming, Disease, Science, University, Lancet Neurology, Genetics, Hope, Research, Parkinson's disease, Biology, Diagnosis, NIH, African Americans, Learning, UCL, Fisher Center for Alzheimer's Research Foundation, AMP, Publishing, Blood, Neurology, Edmond, The Lancet, GP2, University College London, 23andMe, Partnership, ASAP, Glucocerebrosidase, Pharmaceutical industry, Vaccine, GBA1

The discovery of a novel GBA1 variant came from a comprehensive first-of-its-kind genome-wide assessment led by GP2 in 1,488 people with PD and 196,430 control volunteers of African and African admixed ancestry.

Key Points: 
  • The discovery of a novel GBA1 variant came from a comprehensive first-of-its-kind genome-wide assessment led by GP2 in 1,488 people with PD and 196,430 control volunteers of African and African admixed ancestry.
  • BLAAC PD is a cross-sectional study collecting a blood or saliva sample and clinical data from Black and African Americans.
  • ASAP launched GP2 in 2019, building on previous funding efforts from MJFF to expand global genetics study in populations traditionally underrepresented in research.
  • Fox Foundation supported the Edmond J. Safra Global Genetics Consortia to generate and share genetics data in varied international populations.

Global Consortium Identifies Novel Parkinson's Genetic Risk Factor in African Populations

Retrieved on: 
Thursday, August 24, 2023
Alcohol-related dementia, PD, Alzheimer's disease, Ashkenazi Jews, The Michael J. Fox Foundation, Doctor of Philosophy, MJFF, MD, Risk, Genetic programming, Disease, Science, University, Lancet Neurology, Genetics, Hope, Research, Parkinson's disease, Biology, Diagnosis, NIH, African Americans, Learning, UCL, Fisher Center for Alzheimer's Research Foundation, AMP, Publishing, Blood, Neurology, Edmond, The Lancet, GP2, University College London, 23andMe, Partnership, ASAP, Glucocerebrosidase, Pharmaceutical industry, Vaccine, GBA1

The discovery of a novel GBA1 variant came from a comprehensive first-of-its-kind genome-wide assessment led by GP2 in 1,488 people with PD and 196,430 control volunteers of African and African admixed ancestry.

Key Points: 
  • The discovery of a novel GBA1 variant came from a comprehensive first-of-its-kind genome-wide assessment led by GP2 in 1,488 people with PD and 196,430 control volunteers of African and African admixed ancestry.
  • BLAAC PD is a cross-sectional study collecting a blood or saliva sample and clinical data from Black and African Americans.
  • ASAP launched GP2 in 2019, building on previous funding efforts from MJFF to expand global genetics study in populations traditionally underrepresented in research.
  • Fox Foundation supported the Edmond J. Safra Global Genetics Consortia to generate and share genetics data in varied international populations.

Curi Bio Awarded Over $4.4M in NIH Grants to Advance Translational Science

Retrieved on: 
Wednesday, August 23, 2023
Biotechnology, Health, Science, Stem Cells, Research, Transfer, National Center for Advancing Translational Sciences, 23andMe, Tibbetts Award, University, Fast, Duchenne muscular dystrophy, Therapy, Spasm, Bio, SBIR, Principal investigator, 3D, NCATS, Cosmetics, Multimedia, Grant, Bangladesh Technical Education Board, Organization, Press release, Food and Drug Administration, Neuromuscular junction, Animal, DMD, University of Washington Department of Bioengineering, SBA, Drug discovery, Small business, Emergency medical technician, Broadcom Inc., Small Business Innovation Research, B cell, Chronic pain, NIH, Food, Disease, Pharmaceutical industry, Qualcomm, Symantec

The second initiative will deliver a novel 3D neuromuscular junction used for disease modeling and potency assays for pharmaceuticals and cosmetics.

Key Points: 
  • The second initiative will deliver a novel 3D neuromuscular junction used for disease modeling and potency assays for pharmaceuticals and cosmetics.
  • These grants, the first of their kind received by Curi Bio from the National Center for Advancing Translational Sciences (NCATS), demonstrate the impact that the company's innovative 3D tissue platforms have made in developing new medicines.
  • These latest awards bring the total non-dilutive funding that Curi Bio has received from the NIH to over $12 million.
  • This content is solely the responsibility of Curi Bio and does not necessarily represent the official views of the National Institutes of Health.

23andMe Reports FY2024 First Quarter Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Acceleration, FirstBank Holding Co, Database, 23andMe, GSK, Advertising, Interim, Total, Telehealth, Depression, Table, Genetics, Sickle cell trait, Marketing, PRS, Food and Drug Administration, ML, Indigenous, PGS, Lupus, Consumer service, Native Americans, Morehouse School of Medicine, Net, Panic, EBITDA, Patient, Drug discovery, Sickle cell disease, Consumer, Growth, Entrepreneurship, Research, Adjustment, FDA, Food, Genome, Agricultural Research Service, Pharmaceutical industry, Mobile phone, CD200R1, Webcast, Therapy

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, reported its financial results for the first quarter (Q1) of fiscal year 2024 (FY2024), which ended June 30, 2023. 23andMe is the only company with multiple U.S. Food and Drug Administration (FDA) authorizations for over-the-counter genetic health reports. 23andMe also has the largest crowdsourced platform for advanced genetic research, which enables the Company to deliver ongoing genetic reports, new health features and new risk predictions to customers annually. The platform also accelerates the identification of novel drug discovery programs rooted in human genetics across a spectrum of disease areas. 23andMe’s platform was built to help people access, understand, and benefit from the human genome.

Key Points: 
  • Webcast at 4:30 pm ET, August 8, 2023
    SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, reported its financial results for the first quarter (Q1) of fiscal year 2024 (FY2024), which ended June 30, 2023.
  • 23andMe is the only company with multiple U.S. Food and Drug Administration (FDA) authorizations for over-the-counter genetic health reports.
  • “The Company made solid progress this past quarter across both our Therapeutics and Consumer businesses,” said Anne Wojcicki, Co-Founder and CEO of 23andMe.
  • The guidance assumes the following:
    23andMe will host a conference call at 4:30 p.m. Eastern Time today, August 8, 2023 to discuss the financial results for Q1 FY2024 and report on business progress.